Paving the Path to Prevention: Managing Early Treatments for T1D Progression : Episode 6

Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes

January 20, 2025

By Javier Morales, MD, FACP, FACE
Shira Eytan, MD, FACE

Opinion

Video

Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.

EP: 1.Living with Type 1 Diabetes

EP: 2.Screening Guidelines for Type 1 Diabetes

EP: 3.Stages and Symptoms of Type 1 Diabetes

EP: 4.Impact of Delayed Intervention in Stage 2 Type 1 Diabetes

EP: 5.Types of Antibody Screening Tests for Type 1 Diabetes

Now Viewing

EP: 6.Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes

EP: 7.Patient Selection For Teplizumab and Infusion Process

EP: 8.Final Thoughts on Identifying and Managing Patients with T1D

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!